NY-WISE
11.5.2021 12:02:04 CEST | Business Wire | Press release
Wise today announces an integration to bring Wise Platform to Google Pay users. Starting today, Google Pay users in the U.S. on iOS and Android devices are able to send money to their friends and family abroad within the Google Pay app, with access to Wise’s fast, cheap, and transparent services. The initial launch will enable Google Pay users in the U.S. to send money to Google Pay users in India and Singapore, with global send money capabilities to people in Wise’s 80+ country network later this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005412/en/
Wise Platform allows banks, businesses and software companies to tap into the Wise network, giving them and their customers access to cheaper, faster international payments, all through an integrated customer experience. Through the Wise Platform APIs, Google Pay’s U.S. users can now send money to friends and family internationally through Wise - all within the convenient Google Pay app.
The Wise Platform was built to bring international payments into the 21st century, and is now used by banks and businesses in over 10 markets. Wise’s APIs replace the existing patchwork systems banks and other payment providers use to move money internationally. In doing so, Wise enables consumers and businesses around the world to move money internationally faster and cheaper than ever before.
The initial integration of Wise Platform will be for U.S. Google Pay users sending money to friends and family using Google Pay in India and Singapore. Providing people with a simple and seamless way to send money to friends and family is more important than ever - particularly in India which is currently experiencing a devastating second wave of the coronavirus pandemic. According to The World Bank, India is the world’s foremost remittance destination.1 In Singapore, international inbound remittances have consistently grown since 2013, showing an increased demand among consumers for international payment services, such as Wise.2
Now, Google Pay customers in the U.S. can send money to India and Singapore with Wise without having to leave the Google Pay platform. And, unlike most banks and payments companies, Wise uses the real exchange rate with no hidden fees or markups. On average, Wise is eight times cheaper than most banks to send money internationally, saving its customers over $1 billion a year.
"Providing people with a simple and seamless way to safely send money to friends and family is more important than ever - be it for everyday use or in times of need," said Harsh Sinha, Chief Technology Officer at Wise. “Wise’s mission is money without borders - instant, convenient, transparent, and eventually, free. Through this collaboration, and with the integration of the Wise Platform, Google Pay customers can now send money internationally cheaper, faster, and easier.”
"Cross-border payments are not just a lifeline for loved ones, they form the financial backbone for many economies," said Josh Woodward, director of product management, Google Pay. "For many people with families abroad, sending money home is something they do as frequently as every month. By teaming up with Wise, we are providing a way for Google Pay users to send money quickly, safely and reliably from the Google Pay app."
For new customers, Wise will make the first transfer free on transfers up to USD$500 until June 16. By the end of the year, U.S. Google Pay users will be able to send money to 80 countries through Wise.
For more information on Wise Platform and capabilities, visit wise.com/us/business/api .
About Wise
Wise is a global technology company, building the best way to move money around the world. With the Wise account people and businesses can hold 54 currencies, move money between countries and spend money abroad. Huge companies and banks use Wise technology too; an entirely new cross-border payments network that will one day power money without borders for everyone, everywhere. However you use the platform, Wise is on a mission to make your life easier and save you money.
Co-founded by Taavet Hinrikus and Kristo Käärmann, Wise launched in 2011 under its original name TransferWise. It is one of the world’s fastest growing tech companies having raised over $1 billion in primary and secondary transactions from world leading investors.
10 million people and businesses use Wise, which processes over £4.5 billion in cross-border transactions every month, saving customers over £1 billion a year.
1
The World Bank: The Remittance Market in India
2
Ken Research: Singapore International Remittance Market Outlook to 2023 - By Inbound & Outbound Remittance, By Banking and Non-Banking Channel, By Inflow & Outflow Remittance Corridors
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005412/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
